FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207069321> ?p ?o ?g. }

• W4207069321 abstract "Dear Editor, Here, we report the therapeutic properties of a small molecule agonist of the CXCR4 receptor on the recovery from the peripheral flaccid neuroparalysis caused by Bungarus snakebites. Snake envenoming is a neglected disease that, each year, causes >100 000 deaths in tropical and sub-tropical areas of the world and leaves >400 000 envenomed patients with permanent disabilities, with associated high social costs (https://www.who.int/news-room/fact-sheets/detail/snakebite-envenoming). This is a disease of poverty believed by experts to be under reported.1 Moreover, snake envenoming strikes particularly in lower income and rural parts of the world where advanced hospital care may not be rapidly available to the envenomed patient. A major number of neuropathological snakebites are produced by snakes of the Bungarus genus widely distributed in Asia.2 Their venoms induce a descending flaccid paralysis with respiratory failure and autonomic dysfunctions. A large reduction of the function of the neuromuscular junction (NMJ) can be recorded electrophysiologically within few hours from snakebite,2 and death may occur by respiratory failure. Mechanically ventilated patients survive because the Bungarus neurotoxins do not kill motor neurons but induce a rapid degeneration limited to the axon terminals which is followed by a slow regeneration requiring prolonged hospitalization (3–5 weeks) and eventual recovery.2, 3 However, hospitalization with mechanical ventilation poses major problems in low-income countries associated with high costs and risks of in-hospital complications. The pathophysiology of Bungarus snake envenoming is primarily driven by neurotoxicity caused by protein neurotoxins.2, 3 The presynaptically acting β-bungarotoxins (β-BTX) are phospholipases A2 that cleave the ester bond of the fatty acid in the sn-2 site of the glycerol moiety of phospholipids, causing accumulation of fatty acids and lysophospholipids leading to rapid degeneration of axon terminals within few hours in mice.4 This is followed by regrowth of the motor axon terminal with reformation of a functional NMJ. This remarkable process is almost complete within about a week in young mice and can be monitored by imaging the NMJ using presynaptic protein markers and by electrophysiology. Recently we discovered that the degeneration of the motor axon terminal is accompanied by the expression of the CXCR4 receptor on the neuronal plasma membrane5 and that a small molecule CXCR4 agonist, dubbed NUCC-390,6 promotes the recovery of function of the NMJ degenerated by the spider α-latrotoxin.7 Therefore, we investigated the utility of NUCC-390 in treating neurotoxicity induced by the venoms of three most common Asiatic krait species, that is, Bungarus caeruleus, Bungarus candidus and Bungarus multicinctus.8 Figure 1 and Figure S1 show that the venoms cause a rapid and complete degeneration of the motor axon terminals leaving intact the convoluted post-synaptic structure of the NMJ. This is accompanied by the surface expression of the CXCR4 receptor (Figure 1 Suppvideo), and the CXCR4 staining is concentrated on nerve axon stumps close to perisynaptic Schwann cells (Figure S2). CXCR4 persists for a long time period, to decline by day 7, when recovery of the NMJ is accomplished. Figure 1 also shows that this phenomenon is due to β-BTX and not to α-BTX which is a post-synaptic neurotoxin present in some of the Bungarus venoms. These findings provide the basis for testing the effect of the CXCR4 receptor agonist NUCC-390 on NMJ anatomical and functional regeneration. Functional recovery of the NMJ was quantitatively assessed by electrophysiology performed on single muscle fibres (evoked junctional potential) or on the muscle (compound muscle action potential [CMAP]). Figure 2 shows that NUCC-390 accelerates the recovery of NMJ function from the neuroparalysis caused by three different Bungarus venoms or β-BTX. Figure 2D shows that the NUCC-390 effect is mediated by its action on the CXCR4 receptor as it is completely prevented by the very specific antagonist AMD3100. This finding on single muscle fibres is paralleled by the one assessed on the entire muscle by the measurement of CMAP (Figure 3) and by imaging the NMJ using the specific presynaptic marker vesicle-associated membrane protein isoform-1 (VAMP-1) (Figure S3). As Bungarus envenoming results in deficit of lung ventilation,2, 3 NUCC-390 was tested on the recovery of the respiratory function in envenomed mice using a very sensitive and minimally invasive test. A probe connected to a pressure sensor was placed inside the esophagus at the mediastinum level in anesthetized mice. Figure 4 shows the recorded signal characterized by asymmetric peaks with a frequency corresponding to events of lung ventilation. The peak area provides an estimate of the volume of air inspired which results from the activity of respiratory muscles. Bungarus venoms decrease both frequency and extent of ventilation with changes in shape and dimension of each peak (Figure 4A). NUCC-390-treated animals showed an increase in peak area compared to untreated mice after 24 h, and this effect amplified with time. At 96 h, NUCC-390-treated mice showed a complete recovery in lung ventilation, a result reached by control animals only after 1 week. A quantitative analysis shows that, after the initial decline due to envenomation (4-h point in the graph of panel C of Figure 4), NUCC-390 accelerates the recovery of ventilation after envenomation (panel B) as compared to controls. This functional recovery is accompanied by the restoration of the structure of diaphragm NMJs as shown in Figure 4D. Taken together, the data presented here qualify NUCC-390 as a novel potential therapeutic to accelerate nerve structural and functional recovery from the neurodegeneration and paralysis caused by Bungarus snake envenoming. The molecule is stable, non-toxic, of simple chemical synthesis7 and does not suffer from the limitations of anti-venom antisera because its efficacy does not depend on the species specificity and origin of the antiserum and can be administered also even days after snakebite.9, 10 In fact, NUCC-390 is complementary to antisera because of its different mechanism of action which leads to a more rapid recovery from a peripheral neuroparalysis, thereby shortening the mechanical ventilation period with a parallel decrease of healthcare costs. This is important particularly in developing countries where most of neuroparalytic snakebites occur. These properties and considerations support the proposal of a rapid translation of NUCC-390 to trials in envenomed patients. This work was supported by the funding from the University of Padova and by the project “RIPANE” of the Italian Ministry of Defense. We would like to thank Dr. M. Pirazzini for critical reading the manuscript. The authors declare no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article." @default.
• W4207069321 created "2022-01-26" @default.
• W4207069321 creator A5010509601 @default.
• W4207069321 creator A5020920288 @default.
• W4207069321 creator A5036209633 @default.
• W4207069321 creator A5040261148 @default.
• W4207069321 creator A5058650456 @default.
• W4207069321 creator A5059150976 @default.
• W4207069321 creator A5063642210 @default.
• W4207069321 creator A5065244580 @default.
• W4207069321 creator A5065776889 @default.
• W4207069321 creator A5072457581 @default.
• W4207069321 creator A5076153026 @default.
• W4207069321 creator A5091033956 @default.
• W4207069321 date "2022-01-01" @default.
• W4207069321 modified "2023-10-16" @default.
• W4207069321 title "An agonist of the CXCR4 receptor is therapeutic for the neuroparalysis induced by <i>Bungarus</i> snakes envenoming" @default.
• W4207069321 cites W1974613712 @default.
• W4207069321 cites W2051583331 @default.
• W4207069321 cites W2080523723 @default.
• W4207069321 cites W2086692004 @default.
• W4207069321 cites W2265676224 @default.
• W4207069321 cites W2504150820 @default.
• W4207069321 cites W2617691195 @default.
• W4207069321 cites W2976922937 @default.
• W4207069321 cites W3156438720 @default.
• W4207069321 cites W3174205332 @default.
• W4207069321 doi "https://doi.org/10.1002/ctm2.651" @default.
• W4207069321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35075797" @default.
• W4207069321 hasPublicationYear "2022" @default.
• W4207069321 type Work @default.
• W4207069321 citedByCount "4" @default.
• W4207069321 countsByYear W42070693212022 @default.
• W4207069321 countsByYear W42070693212023 @default.
• W4207069321 crossrefType "journal-article" @default.
• W4207069321 hasAuthorship W4207069321A5010509601 @default.
• W4207069321 hasAuthorship W4207069321A5020920288 @default.
• W4207069321 hasAuthorship W4207069321A5036209633 @default.
• W4207069321 hasAuthorship W4207069321A5040261148 @default.
• W4207069321 hasAuthorship W4207069321A5058650456 @default.
• W4207069321 hasAuthorship W4207069321A5059150976 @default.
• W4207069321 hasAuthorship W4207069321A5063642210 @default.
• W4207069321 hasAuthorship W4207069321A5065244580 @default.
• W4207069321 hasAuthorship W4207069321A5065776889 @default.
• W4207069321 hasAuthorship W4207069321A5072457581 @default.
• W4207069321 hasAuthorship W4207069321A5076153026 @default.
• W4207069321 hasAuthorship W4207069321A5091033956 @default.
• W4207069321 hasBestOaLocation W42070693213 @default.
• W4207069321 hasConcept C126322002 @default.
• W4207069321 hasConcept C170493617 @default.
• W4207069321 hasConcept C2778938600 @default.
• W4207069321 hasConcept C71924100 @default.
• W4207069321 hasConcept C98274493 @default.
• W4207069321 hasConceptScore W4207069321C126322002 @default.
• W4207069321 hasConceptScore W4207069321C170493617 @default.
• W4207069321 hasConceptScore W4207069321C2778938600 @default.
• W4207069321 hasConceptScore W4207069321C71924100 @default.
• W4207069321 hasConceptScore W4207069321C98274493 @default.
• W4207069321 hasIssue "1" @default.
• W4207069321 hasLocation W42070693211 @default.
• W4207069321 hasLocation W42070693212 @default.
• W4207069321 hasLocation W42070693213 @default.
• W4207069321 hasLocation W42070693214 @default.
• W4207069321 hasOpenAccess W4207069321 @default.
• W4207069321 hasPrimaryLocation W42070693211 @default.
• W4207069321 hasRelatedWork W1506200166 @default.
• W4207069321 hasRelatedWork W1995515455 @default.
• W4207069321 hasRelatedWork W2042405111 @default.
• W4207069321 hasRelatedWork W2080531066 @default.
• W4207069321 hasRelatedWork W2141926683 @default.
• W4207069321 hasRelatedWork W2748952813 @default.
• W4207069321 hasRelatedWork W2899084033 @default.
• W4207069321 hasRelatedWork W3031052312 @default.
• W4207069321 hasRelatedWork W3032375762 @default.
• W4207069321 hasRelatedWork W3108674512 @default.
• W4207069321 hasVolume "12" @default.
• W4207069321 isParatext "false" @default.
• W4207069321 isRetracted "false" @default.
• W4207069321 workType "article" @default.